AI
AI Weekly Scanner Performance Check
63% of our scanner picks gained 15%+ within 45 days. Here's the full breakdown across 17 weeks.
Catalyst
Biotech Investing
🧬 BIOTECH CATALYST A SCANNER — March WK1
(Editor's note) The evolving geopolitical landscape in the Middle East warrants close attention from market participants. Elevated volatility may pressure near-term returns; however, it can also open selective opportunities for investors with appropriate risk tolerance and a long-term perspective. Above all, we stand in solidarity with
AI
🧬 BIOTECH CATALYST AI SCANNER – January WK3
Last week's 44th annual J.P. Morgan Healthcare Conference closed with a whimper rather than a bang. The industry's premier gathering—where mega-deals typically set the tone for the year—delivered what prominent biotech investor Brad Loncar called "the slowest JPM for news in
AI
🧬 BIOTECH CATALYST AI SCANNER – January WK2
Takeover Rumors Swirl Around Revolution Medicines and Abivax as Industry Giants Hunt for Blockbusters The 44th Annual J.P. Morgan Healthcare Conference officially begins today, January 12, 2026, setting the stage for what analysts are already calling a "banner year" for biopharma M&A. The dealmaking atmosphere
Catalyst
The Biotech Edge: Analyzing 8,000 Catalysts to Find the Alpha
Data-driven biotech investing: Biostockinfo reveals how clinical catalysts, anticipation run-ups and Breakthrough Therapy designations create alpha for independent retail investors.
AI
🧬 BIOTECH CATALYST AI SCANNER — November WK3
After an extremely tough week for the biotech sector—and the broader market—we're finally seeing signs of recovery. With the government shutdown issue now resolved, the sector should hopefully regain momentum in the coming weeks. From last week's top 15 picks, IFRX and GLTO showed